Angiotech Shares Up on Taxus Registry Data
14th Mar 2006, 21:34 GMT
Shares of Vancouver-based Angiotech Pharmaceuticals rose after its partner Boston Scientific said preliminary 6-month registry data for its Taxus Express2 drug-coated heart stent confirmed previous safety data.
Angiotech Shares Up on Taxus Registry Data related news:
- Angiotech Shares Up on Taxus Registry Data — Radiology News from StratCenter.com
- STENT registry safety data favors TAXUS(R) over Cypher(R) in the most complex diabetic patientsComplex insulin-treated diabetic population shows numerical trend toward improved MACE outcomes with TAXUS versus Cypher — mysan.de - Lifestyle News
- STENT registry safety data favors TAXUS over Cypher in the most complex diabetic patients — Radiology News from StratCenter.com
- ARRIVE II Registry Demonstrates Low 2.5% TAXUS-Related Re-Intervention Rate in Complex Lesions — Cardiology News from StratCenter.com
- STENT Registry Safety Data Favors TAXUS(R) Over Cypher(R) in the Most Complex Diabetic Patients — PR Newswire: All Releases
- New Data Suggest Differences in Clinical Performance Between the CYPHER Sirolimus-Eluting Coronary Stent and the Taxus Stent in Long Complex Lesions — Radiology News from StratCenter.com
- Intro To The Windows Registry — Lockergnome's Windows Fanatics
- Registry of Mass Spectral Data reaches 8th edition — Services latest news on Laboratorytalk
- Angiotech Proceeding With $785M Deal — Pharmaceuticals News from StratCenter.com
- Forex Trading News: - Asian shares flat, dollar softer before U.S. data — Insider Forex Trading
Latest news from Angiography/ Cardiac Cath News from StratCenter.com:
- Thinking Systems Releases Enhanced PET-CT Functions for Its ThinkingPACS
- Tallahassee Memorial Hospital at the Forefront in Treatment of Heart Attack Patients
- Preliminary Long-Term Clinical Data Show Promising Results for the CYPHER Sirolimus-eluting Coronary Stent in Patients With Multi-Vessel Disease